Aardvark Therapeutics (AARD) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Milestone Pharmaceuticals (MIST) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 59.5% versus a loss of 69.6%. Milestone Pharmaceuticals is the larger company by market cap ($100.3 million vs $97.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | MIST |
|---|---|---|
| Share price | $4.45 | $0.8055 |
| Market cap | $97.39M | $100.28M |
| 1-day change | -6.51% | +5.29% |
| YTD return | -66.10% | -60.12% |
| 1-year return | -69.58% | -59.52% |
| 5-year return | — | -85.50% |
| EPS (TTM) | $-3.21 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.60 | $3.06 |
| 52-week low | $3.35 | $0.707 |
| Distance from 52-week high | -73.19% | -73.68% |
| Analyst consensus | buy | none |
| Avg. price target upside | +149.66% | +627.50% |
| Average volume | 146.39K | 1.41M |
| Shares outstanding | 21.88M | 124.50M |
| Employees | 28 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MIST has outperformed AARD by 10.1 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
AARD vs MIST FAQ
Which is bigger, Aardvark Therapeutics or Milestone Pharmaceuticals?
Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $100.28M compared with $97.39M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or MIST?
MIST returned -59.52% over the past 12 months, compared with -69.58% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Milestone Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.